SR-8278 is an experimental drug that was developed as an antagonist of Rev-ErbAα.[1] It has been used to demonstrate potential applications of Rev-ErbAα antagonists in the treatment of conditions such as Duchenne muscular dystrophy and Alzheimer's disease.[2][3]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H19NO3S2 |
Molar mass | 361.47 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Kojetin D, Wang Y, Kamenecka TM, Burris TP (February 2011). "Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB". ACS Chemical Biology. 6 (2): 131–4. doi:10.1021/cb1002575. PMC 3042041. PMID 21043485.
- ^ Welch RD, Billon C, Valfort AC, Burris TP, Flaveny CA (December 2017). "Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle". Scientific Reports. 7 (1): 17142. Bibcode:2017NatSR...717142W. doi:10.1038/s41598-017-17496-7. PMC 5719458. PMID 29215066.
- ^ Lee J, Kim DE, Griffin P, Sheehan PW, Kim DH, Musiek ES, Yoon SY (February 2020). "Inhibition of REV-ERBs stimulates microglial amyloid-beta clearance and reduces amyloid plaque deposition in the 5XFAD mouse model of Alzheimer's disease". Aging Cell. 19 (2): e13078. doi:10.1111/acel.13078. PMC 6996949. PMID 31800167.